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Commentary
DR. KRAMER COMMENTS ON PSYCHOACTIVITY OF CA LC IU M C HANN EL
BLOCKERS, CASE REPORTS, AND RESEARCH
Sir:
Price and Heil are riding the wave of curiosit y about th e ro le o f ca lcium cha nnel
blockers in th e treatment of psychiatric disorders. These authors, a senior reside nt and a
medical student, hav e taken time to review literature a nd to organize the ir observations
for publication. Dr. Pri ce has previously reported, in late 1985, on a fa irl y careful, bu t
nonparallel group design study on th e antipsychotic effec ts o f verapamil in eigh t
schizophrenics. These efforts are to be commended. It is th e appropriat e begin nin g fo r
more detailed and scholarly research. It would be enc o urag ing to see more of th is act ivit y
here and elsewhere.
The authors are aware of some of th e limitations of th eir specific co ncl usions and
those that , in general, accompany case reporting. While th e fo llow ing co mm ents are
somewhat specifically applicab le to Pri ce a nd Heil's present pap er, th ey also serve to
di scuss the sho rtco m ings of many of th e case reports th at are publ ished th ese days.
Time alone, repeated " therape utic" contacts, and fluctuations in th e na tural course
of psychotic disorders are all factors which ma y influence o utcome measu res. Fo r
instance, we have re cently co mpleted a pla cebo-controlled double-blind stud y o n the use
of two different adjunctive antidepressants in 90 schizoaffective, mainly sch izophrenic,
patients . One minor and expected result was that th e patients, irrespective of th ei r
experimental treatment group assignment, were rated as significantly improved afte r
nine weeks of evaluation and treatment. This type of outcome sho uld dissuad e case
reporters from drawing an y but the most tentative co nclusio ns fr om a sa mple of o ne. It is
also risk y to be decisive about the me aning of data co llec ted from a large sa mp le wit ho ut
parallel pla cebo or other parallel co ntrol groups.
Pri ce and Heil co uld have instituted a few simple design and wr ite -up techn iq ues tha t
ma y hav e allowed th em and us to make some very tentative co nclus ions:
I. Diagnosis. It is assumed that their patient was sch izophren ic. This should be
specifically stated, and, if possible, th e criteria method of diagnosis reported (DSM-Ill,
Feighner, Research Diagnostic Criteria, etc.),
2. Quantification of Outcome. A simple rating instrument , like th e Brief Psych ia t r ic
Rating Scale, could give us a better idea ofthe magnitude of th e beh avioral distu rbances
and improvement in the patient. In addition , an instrument like th e Scale for the
Asse ssm ent of Negative Symptoms (SANS, Dr. Nan cy Andreason) co uld be employed in
an y future trials of verapamil in schizophrenia .
3. Repeated Crossovers. How would outcome measures be influenced if the a uthors
swit ched th e patient ba ck to placebo, and th en to verapamil o r haloperidol again? A
positive relationship between improved outcome ratings o n ly during verapamil treat -
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ment periods would lend credence to the possible e fficacy of verapamil in this "schizo-
phrenic" patient.
4. Unbias the Rater, Unbias the Patient. Patient and Rater expecta tions of trea t-
ment outcome may significantly influence results. I am impressed with th e number of
patients who " improve dramatically" simply because of their transfer to a friendly
research unit, or upon receiving the new " magic medicin e. " While I may bel ieve that thi s
placebo effect represents a "real" biological change in the patient , I mu st not allow
myself to conclude that the specific treatment, unless contrasted with placebo o r o the r
control, is the important factor. I remember that during one of my double-bl ind
placebo-controlled studies, I tried to guess the identity of the encoded medi cati on s. My
guesses were incorrect. Nevertheless, had I been an "unbl ind" rat er, I wo uld have
unconsciously augmented the outcome measures of many of th e placebo-treat ed pati ents,
who I thought were being treated with active medications. If possible , it is worth wh ile to
co nsider en capsulating all medications within opaque capsules, and to util ize a b lind
rat er.
5 . Consider Alternative Reasons for an Apparent Treatment Effec t. Wh y do the
negative (and positive) symptoms of schizophrenia seem to improve in thi s verapamil -
treated patient? Perhaps the improvement was due to the patient's previo us respo nse
(improvement in positive symptoms) to haloperidol , time off neu roleptics, subseque nt
diminution of neuroleptic-induced akinesia and sedation (improveme nt in nega tive
symptoms), and a further relapsing/remitting course, followed by relative remission.
This is not an unusual direction for schizophrenia, and could be independent of
verapamil treatment. We need to be free of the myth that sch izophre nics need co nsta nt
inpatient doses of neuroleptics. The emerging trend today is to treat th ese pati ents with
very small doses of neuroleptics, until th eir target symptoms reemerge. This st rategy
seems to d imin ish the "negative" symptoms of schizophrenia. I think our " no ncom-
pliant" patients have practiced this all along.
Eight months ago Drs. P. DeMaria, A. Mirow (both J efferson resid ents) a nd mysel f
co mpleted a study and later submitted a paper for publication (under review), to the
Journal of Clinical Psychopharmacology, on a double-blind , placebo-controlled double
crossover study on the use of 60 mg (daily) of nifedipine (a calcium channe l blocker) in
five DSM-lII diagnosed schizophrenics. In consideration of our small sample and lack of
parallel group design , we cautiously concluded that nifedipine lacked an ant ipsyc hotic
e ffect. The patients appeared to be clinically less arnotivated, an ergic, and/or asocia l.
Yet, this finding was not corroborated by specific BPRS item scores, nor co nfined to th e
nifedipine period. One patient did " improve dramatically" (clinically and wit h BPRS
decreases of about 35 percent), but this also was not co nfine d to th e ac tive treatme nt
period. One patient had about a 25 percent increase in BPRS scores after neu rol eptic
withdrawal and placebo or nifedipine treatments. While it can be argued that ni fedipine
was effective in one patient, it is more likely that neuroleptic withdrawal was respon sibl e
for the apparent activation and other alterations in clinical sta te of mo st of th e pati e nt s.
There is the remote possibility that nifedipine ma y have potential e fficacy for the
negative symptoms of schizophrenia. However, we've decided to first in vest igate wheth er
nifedipine is an antidepressant. Drs. K. Caputo, L. Maldonado, A. Mirow, and F.
Sholevar , all Jefferson residents, have joined me in this investigation of nifedipine in ten
e ndogeno usly depressed patients. We are more than half-w ay through thi s double-bl ind
symmetr ica l placebo-controlled crossover trial.
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I hope tha t these co mments will not discourage case reporting, but ra the r will serve
as so me guidelines for enhanced clinical case reporting, a nd as an indication for th e
necessit y of su bse quent ca refu lly design ed , larger studies .
Mark Kramer, M.D ., Ph. D.
H ead of Division of Biologica l Psychiatry
J effer so n Med ica l College
Chief of Sc hizophrenia Research
Coatesville Ve terans Administration Medi cal Ce nter
[Our wor k mention ed here IS supported as part of the VA Merit Review Grant
Program .]
DR . SH O RE CO MMENTS O N "TREATMENT OF THE NEGATIVE
SY MPTO MS OF SC H IZO PH REN IA WI TH VE RAPAMIL"
Sir:
It is e ncouraging to see papers on new treatme nt approaches to sch izophrenia,
especially those ta rgete d o n negative sym ptoms. Whi le case reports ma y have limited
scientific value, th ey are an excellen t means by which one can progress from clinical
observation to a research o r ientatio n. Reviewing the litera tu re on a topic, synthes izin g a
variety of views and hypotheses, evaluating a therapeutic trial, and writ ing up th e res u lts
in a research paper ca n all serve as important lear n ing exper iences. Man y research
scientists have begun with case reports and then gone on to learn bl ind assessm ent
techniques, dat a ana lysis, an d a host of methodologica l refinements. I beli eve tha t th e
au thors of th is art icle have go tten a pro mising start a nd I en courage th em to co nsider
fur ther research on sch izophrenia .
I was going to prepare a cri t iq ue of t he paper that wou ld illustrate th e utility and th e
po tentia l pitfa lls of case report studies, but after reading Dr. Kramer's exce llent
co mmentary, writing one myself see ms un necessar y. His review of factors such as placebo
effects in non-b lind studies, r elat ed problems with subjective vs. more objective assess-
ments , and variations in th e na tural co urse of psyc hiatric disorders such as schizophren ia ,
is very valuable. I , too , have gotten excited over treatment responses in patients who
turned ou t to be o n placebo. Since the patie nt, ward staff, and ph ysician all wan t (and
per haps ex pect) the pati ent to get better , it is no surprise when that seems to occ ur.
Crossover st ud ies (suc h as th e A/ B/ A design: p lacebo/active drug/placebo period s) can
be very useful , bu t even with this design patients may seem to respond well to the ac tive
drug, but when lat er p laced back on the d rug (A/B/ A/B design), blind assessmen t may
fa il to show the sa me positive response .
Another area that can be pro blema tic for developing research ers is th e lite rature
re view. It is a natural tenden cy to search for papers or other indications that a particul ar
hypo th esis, approach or drug is pro mising . Nevertheless , one must search at lea st as hard
for evidence co ntrary to o ne's idea- sometimes we can avoid reinventing wheels,
sometimes we can devise new speculat ions to explain contradictory results. Of course,
unless one has firsthand ex perience wit h a given technique, assessment, or assay, it is hard
to evaluate conflicting literature . Reside nts are at another disadvantage in th at th ey may
not kn ow of recently complet ed or ongoing studies. T hose who are ab le to read a large
numbe r of scienti fic journals, those who may learn of new studies from rev iewing art icles
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for various journals or from reviewing grant applications, and those who personally know
other scientists working in a given field obviously ha ve an advantage. But none of these
are insurmountable, and just as clinicians graduall y grow in skills and kno wledge , so
researchers develop and learn with whom th ey should co llaborate or consult , what
meetings they should attend, and what journals they sh ould read.
Because of the programs and priorities of the National Institute of Mental Heal th
(N IMH) , I am convinced that this is a particularly ex citing tim e for psychi a t ry res iden ts
interested in schi zophrenia research. There are a number of research , caree r develop-
ment, and research training mechanisms available through N IMH grants a nd intramural
programs, and I would encourage all those interested in sch izophrenia research to learn
about th ese opportunities. A summary of NIMH schizophrenia research programs of
particular relevance for psychiatry residents follows .
David Shore , M.D .
Chie f, Biologi cal and Clinical Factors Research Program
Schizophrenia Research Branch
Division of Clinical Research
National Institute of Mental H ealth
SCHIZOPHRENIA RESEARCH CAREER OPPORT U NI TI ES
Schizophrenia affects at least 1 percent of the population and has been
est imate d to cost the U.S. over 20 billion dollars per yea r in treatment costs and
lost income . Psychiatric residents are wel l aware of th e se ve re di sability caused
by sch izop h renia and th e limits of cu r rently available treatments. Nevertheless,
with the many career options open to th em , sch izop hre nia research is too often
overlooked.
The climate for schizophrenia research ha s be en changing recently, so that
an academic career in this field could be particularly exc it ing. T he co nvergence
of seve ra l facto rs, especially the many recent advan ces in th e neurosciences,
makes those of us on th e staff of th e National Institute o f Mental Health (NIMH)
very enth usiastic about new opportunities . With th e introducti on of non-
invasive scanners such as the CT, MRl , CBF, and PET, research ers have been
able to examine the structure and function of th e brains of schi zophrenic
patients. These stud ies ha ve demonstrated subtle atrophy in schizophrenic
patients' brains and shown differences in metabolism and receptor density
compared to co ntro ls. Along with the emerge nce of these soph isticate d scanning
methods, the biological theories of schizophrenia have also gained momentum.
Examples of this trend include the increase in studies of neurotran smitte rs and
th eir metabolites, pharmacological trials with " stat e of th e science" antipsy-
ch otic medications, measurement of peptides that functi on as neuromodulato rs,
physiological measures such as eye tracking, and molecular gen eti cs.
These advances in clinical applications of ba sic science adva nces are,
however, only part of th e reason th ere is increased enthusiasm in schizop hrenia
research . In th e late 1970s, famil y groups began to organize to decrease thei r
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isolation and advocat e for better mental health ca re. T hese fami ly groups have
become a political fo rce, pressin g legislators to do more in the areas of treatment
a nd research on maj or mental illn esses, a nd th ey ha ve lobbied successfully in
Congress for increa sed fund ing of sch izoph ren ia research a nd research train-
in g.
Resid ents shou ld be informed th at resea rc h o n maj o r me nt a l illnesses such
as sch izophren ia has become a leading priority o f N IMH . T he Institute is
especia lly co ncerned about sch izop hrenia research manpowe r needs, and has
been exp lor ing incentives to de velop a new genera tion of research scientists.
Given th e sh ift toward a more biological approach to schizo phrenia, psychiatry
resid ents and others with biomedical train ing have specia l poten tial for making
co nt r ib ut io ns to sch izoph renia research progress in the co mi ng years. Rapidly
de veloping areas such as molecular genet ics, neurovirology, neurochem istr y,
st ru ctu ra l and functional imaging, and psychopharmacology a ll hold the poten-
tial for breakthroughs in schizophrenia researc h.
Of course , research is not for ever yo ne, a nd th ere have bee n numerous
di sin centives to schizophrenia research careers as noted in th e Spring 1986 issue
of Schizophrenia Bulletin (1). One of th e problems is that , unless a person has been
inv olv ed in resea rch , the re is no sure way to determine whether he or she would
be happy in suc h a role. Medical stu dents and resid ents in terested in research
shou ld seek out opportun ities fo r suc h e xper ience with successfu l investigators.
Man y psychiatry departments ha ve o ngoing research p rojects, a nd N IMH can
provid e lists of sch izop hren ia research gran ts funded in recen t yea rs at institu-
tio ns a ll around th e co u ntry . T hese a re summa r ized in the upcom ing issues of
th e Schizophrenia Bulletin, Volume 13, umbers 1 an d 2. If a given institution
does no t ha ve a research er or program in o ne's area of interest, a fe llowship to
stu dy with a mentor elsewhere may be worth co ns ider ing. In addi t ion to helping
a potential research tra inee decide about th e desir abil ity of this career option,
exper ience in research (and publicati on ) is importa nt in th e re view of research
training applica t io ns.
N IMH now offers th ree research support mech an ism s, two research scien-
tist development mech anism s, an d two research tra in ing mech an isms for sup-
port of developing inv estigators. As a result o f this wide var iety of opportunities,
it is o ften unclear to the potential app lica nt wh ich oppor tu nity is best suited to
his or her needs. As a first ste p , a potential applicant needs to be kn owledgeable
about what these different mechanisms were developed to accom plish, as well as
th e deta ils of their administrative requirements.
1. Research Support Mechanism s: All three of th ese mecha nisms mainly
provide suppor t for research cos ts, but th e applicant ca n ass ign a part of
the budget for his or her ow n salary or for th e sa lary of research
personnel.
A. Small Grant: T he small grants mech anism was developed to provide
funds fo r pil o t wo r k or sta r t up fu nds fo r new invest igato rs. Funds
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are available to a maximum of $25, 000 for a period limi ted to one
yea r (extensions without additional funds are routinely avai lable).
This mechanism is best suite d for di scretely defined studies that can
be completed in about a year within this fu nd ing limi tation . It has
been used successfully in th e past by beginning in vest igato rs.
B. RO I: The investigator-initiated researc h grant is the bread and
butter research funding mechanism o f IMH. It provides research
funds for qualified applicants at qualified insti tutions; up to five
years of funding can be requested with a fu nd ing lim it dete rmined
by th e fiscal needs of th e supported research. T h is mech an ism is
best suited for support of relatively complex stu dies th at require
multiple years of suppor t and ma y be part of a long-range program
of research . It has often been used in th e past by beginn ing
investigators whose work does not fit within th e co nfi nes of the
small grant.
C. FIRST: A new res earch funding mechanism at NIMH designed to
provide salary and research support to th e in vesti gator who has
never before been the princip al investigator on a Public Heal th
service funded grant. This mechanism provides up to $ 100, 000 per
yea r fo r up to five years of support, with a total fundi ng limit of
$350,000; the funds can be used for both salary and th e support of
research expenses. Because of its five yea r durati on an d relatively
large funding limit, th e applicants must ha ve a well th o ugh t out
program of research to support these limits. T h is is a new program
and there is no track record regarding th e review groups' reaction
to th ese app lica t ions. The Institute hopes tha t th e rev iewers will
look upon th ese as opportunities to a llow bright, capa ble young
investigators to begin a research career.
II. Research Scientist Development Award (RSDA) Mech anisms: These
are designed primarily to provide salary support and researc h training
opportunities for developing scientists. Limited funds can be requested
for research suppor t.
A. Physician Scientist Award (PSA): This award is design ed to enhance
the development of physicians in research careers . Five years of
support for salary, as well as up to $10,000 per year for research and
training costs for the first three yea rs and up to $20, 000 per year
for the final two years of support can be requested. Ph ysicians with
little res earch expe r ience have found this mechanism to be quite
helpful as th ey develop into research scientists. A minimum of two
years of post-doctoral ex per ience is required before support can be
granted . .
B. Research Scientist De velopment Award (RSDA) Level I: This
award is design ed to suppor t individuals with outstanding research
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potential who need further super vised research ex perience. Appli-
cants are usually scientists or clinicians with some research experi-
ence or scientists prepared in one di scipline who need supervised
experience in another. Five yea rs of salary, research , and research
training costs can be requested. This me chanism has been remark-
ably successful in helping young investigators develop into indepen-
dent scientists. A minimum of three years of post-doctoral experi-
ence is required before support can be granted.
III. Research Training Mechanisms: In th ese programs, th e primar y goal is
to provide support during a research training interval. Both are fo r a
maximum of three years of post-doctoral training.
A. National Research Scientist Award (N RSA) Individual Fe llowship:
This award is designed to provide stipend support during research
training. Prior to formal submission , th e applica nt must arrange
acceptance by a sponsor who will supervise th e research train ing
exper ience in a facility that has an appropriate env ironment to
provide the proposed research training . Po st-docto ral stipends
range from $ 16,000 to $30 ,000 per year depending on yea rs of
experience. In addition , $3,000 ma y be requested fo r institution al
allowances .
B. Public Health Service (PHS) Epidemiology Fellowsh ip: T his award
is somewhat different from th e other awards described above in
that the first year of suppor t is for training leading to an MPH and
the second and third years of support a re for research experience in
epidemiology at th e NIMH. Recipi ents of th ese awards receive
NIMH appointments equivalent to the intramural Clin ica l Asso-
ciates. Salary support begins at $30,000 for th e first year with
$2,000 increments for each year of support. T he pu rpose of th is
program is to increase th e number of medical professionals in
mental health epidemiology.
IV . NIMH Intramural Research Programs (IR P): Medical Staff (Clin ical
Associate) Fellowships at IMH in Bethesda or at St. Elizabeth's
Hospital in Washington, DC, are available for th ose who a re co mplet-
ing or have completed residency training. Unlike th e ex t ramural grant
programs described in I-III above, th e IRP co nd uc ts research o n its
own campuses, rather than providing grants to o ther institu tio ns.
There are active research programs in sch izoph renia, affec tive and
anxiety disorders, basic neuroscience , imaging, e tc. Medical staff fe l-
lowships are for two years, with a star t ing annual salary of $32,000.
The events described earl ie r ha ve provided th e impetus fo r increased
suppo r t for careers in schizophrenia research, but money and research tools are
not in themselves a reason to make a career decision. The most co mpelling
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reason for more residents and medical students to look at a career in schi zophre-
nia research is that these seriously ill patients need th e help of ded icated and
energe t ic physicians. Developing research psychiatri sts now have increased
opportunities to contribute to advances in finding th e e t iology or bette r
treatments for this severe and chronic mental di sorder.
David Shore , M.D.
Chie f, Biological and Clin ica l
Factors Research Program
Schizophrenia Research Bran ch
Division o f Clin ica l Resea rch
Na tiona l In stitute of Mental Health
Leonard Lash , Ph.D.
Associate Director for Research Training and
Research Resources
Division of Clinical Research
Na tiona l In stitute of Mental Heal th
S. Charles Schulz, M.D.
Chief, Pharmacologic and So matic
Treatments Resea rch Program
Schizophrenia Resea rch Br an ch
Division of Clinica l Research
a tiona l In stitute of Mental Heal th
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